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COMPARATIVE OUTCOMES OF NONABLATIVE AND ABLATIVE ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS
WITH HEMATOLOGIC MALIGNANCIES YOUNGER THAN 50 YEARS
Kim, H.-G., Kim, I., Kim, B.-S., Kim, J.-S., Hong, Y.-S., Yoon, S.-S.,
Lee, J.-S., Park, S., Kim, B.K. Department of Internal Medicine, Seoul
National University, College of Medicine, Seoul, Korea.
Nonablative conditioning in allogeneic stem cell transplantation
has been performed for reducing transplantation-related compli-
cations. In this study, we compared outcomes of nonablative and
ablative conditioning in younger adults less than 50 years with
hematologic malignancies. From Jan. 2001 until Dec. 2004, 105
adult patients younger than 50 years old with hematologic malig-
nancies were transplanted fromHLA-matched donors, using nona-
blative conditioning (n  35) or ablative conditioning (n  70).
The median ages of nonablative and ablative patients were 36 and
33 years, respectively (P  .014). 17% of nonablative patients
received a prior myeloablative transplant, whereas none of the
ablative patients did (P  .001). Neutrophil engraftment (ie, time
to absolute neutrophil count 	0.5  109/L) was faster in the
nonablative group (median, 10 days; range, 0-21 days) than in the
ablative group (median, 18 days; range, 11-38 days) (P  .0001).
The time to reach a platelet count of more than 20 109/L was 13
days (range, 0-35 days) in the nonablative group, compared with 22
days (range, 9-110 days) in the ablative group (P  .006). The
incidence of grades 2 to 4 acute graft-versus-host disease was
similar in patients of nonablative and ablative groups, 17% vs.
24%, respectively (P  .40). 39% of patients in the nonablative
group and 36% of patients in the ablative group developed chronic
graft-versus-host disease (P  .76). The cumulative incidences of
day 100 nonrelapse mortality were 18% in nonablative patients and
21% in ablative patients (P  .88). Overall survival rates for
nonablative and ablative patients were 43% and 35% at 2 years
(P  .72), respectively. Two-year progression free survival rates of
nonablative and ablative patients were both 35%. In conclusion,
nonablative transplantation showed comparable outcomes with ab-
lative transplantation for younger patients less than 50 years with
hematological malignancies.
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DEVELOPMENT OF A UNIVERSAL AND EFFECTIVE MYELOID PROGEN-
ITOR CELL THERAPEUTIC FOR TREATING NEUTROPENIA
Christensen, J.L.1, Smith-Berdan, S.1, Wahedi, M.1, Danenberg, E.1,
Gille, D.1, Brown, W.2, Fong, T.1, Domen, J.1 1. Cellerant Therapeu-
tics, San Carlos, CA; 2. Stanford University, Department of Medicine,
Stanford, CA.
Ablative conditioning for hematopoietic cell transplantation and
accidental or therapeutic exposure to high levels of radiation or
chemicals will result in signiﬁcant loss of myeloid cells, erythro-
cytes, and platelets leading to morbidity and mortality. Myeloid
progenitors freshly puriﬁed from mouse bone marrow have been
found to prevent fatal fungal and bacterial infections in neutro-
penic mice (Blood. 2002;100:4660-4667), as well as protect against
exposure to lethal levels of radiation (J Clin Invest. 2002;109:1579-
1585). However, fresh isolation of cells for wide spread clinical use
is impractical and unfeasible for treating large patient populations.
Our goal is to develop a novel universal treatment that provides
temporary but effective recovery of these blood cells with a stan-
dardized manufactured myeloid progenitor cell therapeutic. We
have developed a method for generating in vitro and cryopreserv-
ing large numbers of myeloid progenitors (MP) from puriﬁed
hematopoietic stem cells (HSC) in serum-free conditions. These
culture-derived MPs are as effective as freshly isolated myeloid
progenitors in preventing death from invasive aspergillosis in neu-
tropenic animals, increasing survival in allogeneic transplantation,
and providing radioprotection following lethal irradiation. Cul-
ture-derived MPs are effective across allogeneic barriers, and do
not cause GVHD. Furthermore, infusion of cryopreserved, pooled
MPs derived from several MHC disparate donors is as effective as
MPs derived from a single allogeneic donor. These results suggest
that our in vitro generated and cryopreserved MPs may be an
effective bridging therapy during hematopoietic recovery. We are
currently developing methods to generate MPs from highly en-
riched human hematopoietic stem cells for clinical testing.
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CELL DOSE AND GRAFT VERSUS HOST DISEASE (GVHD) AFFECT SUR-
VIVAL IN ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLAN-
TATION (ALLOPBSCT) FOLLOWING NON-MYELOABLATIVE (NM) CON-
DITIONING: A SINGLE CENTER EXPERIENCE
Johnson, J.L.1,2, Vusirikala, M.1,2, Chinratanalab, W.1, Brandt, S.1,2,
Shyr, Y.2, Shakhtour, B.2, Kassim, A.2, Jagasia, M.2, Morgan, D.1,2,
Ruffner, K.1,2, Stein, R.2, Greer, J.2, Schuening, F.2, Goodman, S.1,2 1.
Nashville Veterans Administration Medical Center, Nashville, TN; 2.
Vanderbilt University Medical Center, Nashville, TN.
AlloSCT utilizing NM conditioning is hypothesized to minimize
the toxicity of myeloablative regimens while harnessing a potent
graft vs malignancy effect. We sought to identify factors related to
survival in a retrospective analysis of 37 male patients (pts) who
underwent alloPBSCT from HLA-matched related donors be-
tween 8/00 and 5/05 at the Nashville VAMC. All pts received NM
conditioning with 90 mg/m2 ﬂudarabine and 200 cGy TBI.
GVHD prophylaxis consisted of cyclosporine and mycophenolate
mofetil. The median age was 55 years (range 41-66), and the
diseases transplanted included: MM (12); AML (6); CML (2); CLL
(7); NHL (8); and HD (1). The mean cell doses infused were 7.7
(range 3.4-15.4)  106 CD34/kg and 29.1 (range 10.1-64.1) 
107 CD3/kg. Most pts did not become neutropenic; among 17
(46%) who did, the median time to ANC 	500 was 19 days (range
14-29). Primary graft failure occurred in 1 patient. Of evaluable pts
with chimerism data, median time to 100% donor chimerism was
day 28 for CD33 and day 180 for CD3. AGVHD occurred
in 26/37 (70%) pts (grade I in 10 and grades II-IV in 16), and
cGVHD occurred in 16/31 (52%); 5 pts developed extensive
cGVHD. 9 pts required donor lymphocyte infusion for disease
progression. 100-day non-relapse mortality was 14% (all from
aGVHD); 1 death prior to day100 was from disease progression.
Beyond day 100, 10 pts died from disease progression, 2 from
infection and 3 from unknown causes. Kaplan-Meier probabilities
for overall survival (OS) and progression free survival (PFS) at one
year were 56% and 50%, respectively. OS at 3 years was 31%. In
univariate analysis, the development of cGVHD signiﬁcantly corre-
lated with OS (P  .05) and PFS (P  .04). Pts with grades 0-I
aGVHD experienced signiﬁcantly longer OS and PFS compared to
pts with grades II-IV aGVHD (P  .03). Although CD34 and
CD3 doses showed no signiﬁcant association with development of
cGVHD, higher doses of both cell types were associated with all
grades of aGVHD (P .05) and showed a trend toward development
of higher grades of aGVHD (grades II-IV versus grades 0-I) (P .06).
Survival after NM alloSCT in this population is encouraging, al-
though disease progression remains an area for future study. Our
results suggest CD34 and CD3 cell doses should be optimized to
minimize aGVHD as a cause of early death. The correlation between
cGVHD and survival likely reﬂects a graft vs. malignancy effect.
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BONE MARROW TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA
FROM DONOR WITH GAUCHER DISEASE FOLLOWED BY ENZYME RE-
PLACEMENT THERAPY (ERT)
Mrsic, M., Labar, B., Potocki, K., Fumic, K., Stern-Padovan, R.,
Bogdanic, V. University Hospital Zagreb, Department of Internal Med-
icine, Zagreb, Croatia.
Before the era of Enzyme Replacement Therapy (ERT), HSCT
despite limited availability (HLA identical donor) has been used for
the treatment of Gaucher disease. Case Report: Diagnosis of
standard risk acute myeloid leukemia in 32 year old female was
established in May 2002. Disease remission was obtained in June
2002. HLA tests were performed and an HLA identical brother
was found. He had a long history of anemia bone pain. Splenec-
tomy was done in his childhood. According to the medical docu-
mentation Gaucher disease was mentioned but never diagnosed.
Because availability of ERT and severe underlying disease (acute
leukemia) we decided to proceed with HSCT despite donor un-
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